11/20
08:00 am
enlv
Enlivex Adopts Bitcoin Treasury Reserve Strategy
High
Report
Enlivex Adopts Bitcoin Treasury Reserve Strategy
11/14
08:00 am
enlv
Enlivex Announces the Dosing of the First Patient in a Phase I Clinical Trial Evaluating Allocetra in Patients with Psoriatic Arthritis
Medium
Report
Enlivex Announces the Dosing of the First Patient in a Phase I Clinical Trial Evaluating Allocetra in Patients with Psoriatic Arthritis
11/12
08:00 am
enlv
Enlivex Announces the Enrollment and Dosing of the First 10 Patient in the Randomized Phase II Stage of its Allocetra Trial in Patients with Moderate to Severe Knee Osteoarthritis
Low
Report
Enlivex Announces the Enrollment and Dosing of the First 10 Patient in the Randomized Phase II Stage of its Allocetra Trial in Patients with Moderate to Severe Knee Osteoarthritis
10/30
08:00 am
enlv
Enlivex Receives Notice of Allowance for Japanese Patent Application Covering the Use of Allocetra™ in Patients with Osteoarthritis
Medium
Report
Enlivex Receives Notice of Allowance for Japanese Patent Application Covering the Use of Allocetra™ in Patients with Osteoarthritis
9/27
08:07 am
enlv
Enlivex Therapeutics Ltd. (NASDAQ: ENLV) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $6.00 price target on the stock.
Medium
Report
Enlivex Therapeutics Ltd. (NASDAQ: ENLV) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $6.00 price target on the stock.
9/26
08:30 am
enlv
Enlivex Receives Authorization from the Danish Medicines Agency to Initiate the Phase II Stage of its Phase I/II Trial of Allocetra in Patients with Moderate to Severe Knee Osteoarthritis
Medium
Report
Enlivex Receives Authorization from the Danish Medicines Agency to Initiate the Phase II Stage of its Phase I/II Trial of Allocetra in Patients with Moderate to Severe Knee Osteoarthritis
9/24
08:30 am
enlv
Enlivex Announces Positive DSMB Recommendation to Initiate the Phase II Stage of its Phase I/II Trial of Allocetra in Patients with Moderate to Severe Knee Osteoarthritis
Low
Report
Enlivex Announces Positive DSMB Recommendation to Initiate the Phase II Stage of its Phase I/II Trial of Allocetra in Patients with Moderate to Severe Knee Osteoarthritis
9/11
01:46 pm
enlv
All You Need to Know About Enlivex Therapeutics (ENLV) Rating Upgrade to Buy Wed, Sep 11, 2024, 6:00 PM GMT+2 3 min read 0 In this article: Most Powerful Force Impacting Stock Prices Harnessing the Power of Earnings Estimate Revisions Earnings Estimate Re
Low
Report
All You Need to Know About Enlivex Therapeutics (ENLV) Rating Upgrade to Buy Wed, Sep 11, 2024, 6:00 PM GMT+2 3 min read 0 In this article: Most Powerful Force Impacting Stock Prices Harnessing the Power of Earnings Estimate Revisions Earnings Estimate Re
9/9
08:08 am
enlv
Enlivex Therapeutics Ltd. (NASDAQ: ENLV) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $6.00 price target on the stock.
Medium
Report
Enlivex Therapeutics Ltd. (NASDAQ: ENLV) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $6.00 price target on the stock.
8/28
07:57 am
enlv
Enlivex Therapeutics Ltd. (NASDAQ: ENLV) was upgraded by analysts at EF Hutton Acquisition Co. I to a "strong-buy" rating.
Medium
Report
Enlivex Therapeutics Ltd. (NASDAQ: ENLV) was upgraded by analysts at EF Hutton Acquisition Co. I to a "strong-buy" rating.